重组表达系统用于生产稳定病毒样颗粒作为下一代脊髓灰质炎疫苗
Lee Sherry1, Mohammad W Bahar2, Claudine Porta2,3
1Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Nature communications
|January 18, 2025
概括
稳定型脊髓灰质炎病毒样颗粒 (VLP) 为当前疫苗提供了一个有希望的替代方案,可能有助于全球脊髓灰质炎根除工作. 这些VLP表现出可比或增强的免疫性,为下一代脊髓灰质炎疫苗铺平了道路.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 结构生物学 结构生物学
背景情况:
- 从历史上看,脊髓灰质炎病毒引起了人类的重大疾病,疫苗大大降低了患病率.
- 目前的脊髓灰质炎疫苗在实现最终消除疾病方面面临着挑战.
- 缺乏病毒基因组的病毒样颗粒 (VLP) 是一种更安全的疫苗替代品,但需要稳定.
研究的目的:
- 开发和表征稳定型脊髓灰质炎病毒样颗粒 (VLPs) 作为下一代疫苗候选物.
- 为了比较稳定VLPs的抗原性,热稳定性和免疫性与当前的非活化脊髓灰质炎疫苗.
- 阐明VLP稳定和潜在辅助剂作用的结构基础.
主要方法:
- 利用已建立的遗传技术来稳定小儿麻症病毒囊蛋白.
- 在四个重组表达系统中生产了所有三种血清型的脊髓灰质炎病毒VLP.
- 在Wistar大鼠中评估了VLP抗原性,热稳定性和免疫性;进行了结构分析.
主要成果:
- 在所有三种血清型中成功生成稳定型脊髓灰质炎病毒VLP.
- 在临床前模型中,与非活化脊髓灰质炎疫苗相比,稳定型VLP的免疫性已被证明相当或优越.
- 通过结构分析获得了对稳定突变和辅助剂作用的理性理解.
结论:
- 稳定小儿麻病毒VLP是下一代可行的疫苗候选人.
- 这些VLP提供了一种潜在的更安全,更有效的预防脊髓灰质炎的方法.
- 这些发现支持稳定VLP的推进,以实现无脊髓灰质炎的世界.
相关概念视频
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:17Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...